SMMT

Summit Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The Company is engaged in research and development activities, primarily comprising oncology product research activities (including ivonescimab), and anti-infectives program activities. Ivonescimab, is a novel, potential first-in-class bispecific antibody intending to combine the benefits of immunotherapy via a blockade of PD-1 with the anti-angiogenesis benefits of an anti-VEGF into a single molecule. The Company’s preclinical candidate, SMT-738, from the DDS-04 series for development in the fight against multi-drug resistant infections, specifically Carbapenem-resistant Enterobacteriaceae (CRE) infections. It owns a genetics platform and a suite of software-based technologies (Discuva Platform).